Back to Journals » Journal of Blood Medicine » Volume 11

Blood Targets of Adjuvant Drugs Against COVID19

Authors Di Micco P, Di Micco G, Russo V, Poggiano MR, Salzano C, Bosevski M, Imparato M, Fontanella L, Fontanella A

Received 10 April 2020

Accepted for publication 17 June 2020

Published 2 July 2020 Volume 2020:11 Pages 237—241


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 5

Editor who approved publication: Dr Martin H Bluth

Pierpaolo Di Micco,1 Gianluca Di Micco,2 Vincenzo Russo,3 Maria Rita Poggiano,1 Ciro Salzano,1 Marijan Bosevski,4 Michele Imparato,1 Luca Fontanella,1 Andrea Fontanella1

1Internal Medicine Department, Emergency Room Unit, Fatebenefratelli Hospital of Naples, Naples, Italy; 2Centro Diagnostico Varelli, Naples, Italy; 3University Cardiology Clinic, Faculty of Medicine, Skopje, Macedonia; 4Department of Translational Medical Sciences, University of Campania “Luigi Vanvitelli” Monaldi Hospital, Naples 80131, Italy

Correspondence: Pierpaolo Di Micco Email

Abstract: While waiting for the vaccine and/or the best treatment for COVID19, several drugs have been identified as potential adjuvant drugs to counteract the viral action. Several drugs, in fact, have been suggested for their ancillary antiviral role. Viral proteases and peptidases, may interact with well-known drugs such as anticoagulants, antihypertensives, antiserotoninergics and immunomodulants. We here report a basic list of these drugs that include bioflavonoids, heparinoids, ACE inhibitors, angiotensin receptor blockers, antiserotoninergics, and monoclonal antibodies against cytokines that may interact with the viral cycle.

Keywords: COVID19, flavonoid, heparin, ace-inhibitors, interleukin, angiotensin receptor blockers

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]